Monitor the November 2 meeting outcome for shareholder approval of the RSU grants and any potential financing transaction tied to Chairman Mayron's second tranche of RSUs.
Price Chart
Executive Summary
IceCure Medical filed its proxy statement for the annual and special general meeting on November 2, 2026. The meeting includes proposals to re-appoint Deloitte Israel as auditor, approve equity-based RSU grants to CEO Eyal Shamir (404,901 RSUs, ~$1.33M annual value) and Chairman Ron Mayron (230,577 RSUs, ~$513K annual value for the immediate tranche), and discuss FY2025 audited financials. Director Yang Huang will not seek re-election. This is a routine governance filing with no material financial impact.
Key Facts
- Annual and special general meeting scheduled for November 2, 2026.
- Proposal to re-appoint Brightman Almagor Zohar & Co. (Deloitte Israel) as independent auditor.
- CEO Eyal Shamir to receive 404,901 RSUs with annual value of approximately $1,328,075.
- Chairman Ron Mayron to receive 230,577 RSUs in two tranches: 166,577 RSUs immediately and 64,000 RSUs upon completion of a financing of at least $6.5 million.
- Director Yang Huang notified the company he will not seek re-election; no disagreement cited.
- Shareholders of record as of October 5, 2026 are entitled to vote.
Financial Impact
Equity compensation grants to CEO and Chairman with combined annual value of approximately $1.84 million; no impact on revenue or earnings.
Risk Factors
- Potential dilution from RSU grants if fully vested.
- No financial data provided in this filing to assess business performance.
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-106825 |
| Document: ea030766101ex99-3.htm | 0001213900-26-106825 |
| Document: ea030766101ex99-1.htm | 0001213900-26-106825 |
| Document: ea0307661-01.htm | 0001213900-26-106825 |
| Document: 0001213900-26-106825-index-headers.html | 0001213900-26-106825 |
| Document: 0001213900-26-106825-index.html | 0001213900-26-106825 |
| Document: 0001213900-26-106825.txt | 0001213900-26-106825 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 6-K | $1.10 | awaiting T+60 | — | $1.01 (−8.18%) |
Oct 5, 2026 20d ago | 6-K | $1.27 | awaiting T+60 | — | $1.01 (−20.47%) |
Oct 5, 2026 21d ago | 6-K | $1.54 | awaiting T+60 | — | $1.01 (+34.42%) |
Sep 10, 2026 6w ago | 6-K | $2.14 | awaiting T+60 | — | $1.01 (−52.80%) |
Aug 24, 2026 9w ago | 6-K | $2.27 | awaiting T+60 | — | $1.01 (−55.51%) |
Aug 19, 2026 9w ago | EFFECT | $2.52 | awaiting T+60 | — | $1.01 (+59.92%) |
Aug 14, 2026 10w ago | 6-K | $2.82 | awaiting T+60 | — | $1.01 (−64.18%) |
Aug 12, 2026 10w ago | 6-K | $3.11 | awaiting T+60 | — | $1.01 (−67.47%) |
Jul 6, 2026 16w ago | EFFECT | $4.61 $1.59 | ▲ +65.51% | ▲ +67.23% | $1.01 (+78.09%) |
Jun 26, 2026 17w ago | 6-K | $5.26 $1.95 | ▲ +62.93% | ▲ +67.31% | $1.01 (+80.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers